Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of addi...
Main Authors: | Hayato Koba, Taro Yoneda, Hiroko Morita, Hideharu Kimura, Yuya Murase, Nanao Terada, Yuichi Tambo, Masafumi Horie, Kazuo Kasahara, Isao Matsumoto, Seiji Yano |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.15241 |
Similar Items
-
Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis
by: Taisuke Ito, et al.
Published: (2024-01-01) -
Prolonged response to atezolizumab with bevacizumab plus chemotherapy in a patient with lung cancer harboring mutation in EGFR after Afatinib treatment: A case report
by: Hayato Koba, et al.
Published: (2021-12-01) -
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01) -
Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
by: Sun Min Lim, MD, PhD, et al.
Published: (2021-06-01) -
Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)